U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

April 4, 2018 - Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted the company ’s New Drug Application and granted priority review for dacomitinib, a pan-human epidermal growth factor receptor (EGFR) tyrosine...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news